Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 26

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9BXU7

UPID:
UBP26_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 26; Ubiquitin thioesterase 26; Ubiquitin-specific-processing protease 26

ALTERNATIVE UPACC:
Q9BXU7; B9WRT6; Q5H9H4

BACKGROUND:
Ubiquitin-specific-processing protease 26, with alternative names such as Ubiquitin thioesterase 26, regulates key biological pathways through deubiquitination. It plays a significant role in the stabilization of CBX4 and CBX6, crucial for cell reprogramming, and supports the androgen receptor signaling pathway, impacting spermatogenesis.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in spermatogenic failure, X-linked, 6, by affecting gene variants, Ubiquitin-specific-processing protease 26 emerges as a promising target for developing treatments for male infertility disorders. Understanding its role could lead to groundbreaking therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.